Human Papilloma Virus in Oropharyngeal Carcinoma

Authors

  • Pittaya Dankulchai Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Kullathorn Thephamongkhol Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Thong Narawiwat Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Yaowalak Chansilpa Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University

Abstract

Oropharyngeal cancer, the second most common of head and neck cancer patients in Siriraj hospital, is a challenging disease in head and neck squamous cell carcinoma (HNSCC). Although tobacco use is known the predominant risk factor in oropharyngeal oncogenesis. A very interesting etiological linkage between the human papillomavirus (HPV) and a subgroup of HNSCC has recently been established. At this time, in the year of 2011, we have more and more scientifi c data to support that tumor HPV status is a paramount prognostic biomarker for head and neck cancers in terms of tumor control, disease free survival and overall survival. In other words, the group of HPV positive patients has defi nitely better prognosis. In the near future, results from clinical trials on oropharyngeal cancer will inform us the better way how to treat these groups of patients without any compromise in survival and less toxicity.

References

Shope RE. Serial transmission of virus of infectious papillomatosis in domestic rabbits. Proc Soc Exp Biol Med 1935;32:830-832.

de Villiers EM, Weidauer H, Otto H, et al: Papillomavirus DNA in human tongue carcinomas. Int J Cancer 1985;36:575-578.

Devita, Hellman & Rosenberg’s Cancer: Principles & Practice of Oncology, 8th edition.

Lin K, Doolan K, Hung CF, et al. Perspective for preventive and therapeutic HPV vaccines. J Formos Med Assoc 2010;109(1):4-24.

Scheffner M, Huibregtse JM, Vierstra RD, et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin–protein ligase in the ubiqui- tination of p53. Cell 1993;75:495–505.

Jones DL, Munger K. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 onco- protein. J Virol 1997;71:2905–12.

Siriraj Cancer Registry 2008, Siriraj Cancer Center.

Shiboski CH, Schmidt BL, Jordan RC: Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years. Cancer 2005;103:1843– 1849.

Franceschi S, Talamini R, Barra S, et al. Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy. Cancer Res 1990;50:6502–7.

Mashberg A, Boffetta P, Winkelman R, et al. Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. Cancer 1993;72:1369–75.

Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92(9):709-20.

Weinberger PM, Yu Z, Haffty BG, et al. Molecular classifi cation identifi es a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24(5):736-747.

Lassen P. The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother and Oncol 2010;95(3):371-380.

Kumar B, Cordell K, Lee J, et al. EGFR, p16, HPVtiter, Bcl- xl, and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26:3128-37.

Hafkamp H, Manni J, Haesevoets A, et al. Marked differences in survival rate between smokers and nonsmokers with HPV16-assocaited tonsillar carcinomas. Int J Cancer 2008;122:2656-64.

Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta-analysis. Int J Cancer 2007;121:1813-20.

Dayyani F, Etzel CJ, Liu M et al. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinoma (HNSCC). Head & Neck Oncology 2010:2(15).

Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100:261-9.

Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-9.

Lassen P, Eriksen JG, Tramm T, et al. HPV associated p16-expression and response to radiobiological modifi cations of radiotherapy in head and neck cancer : results from the randmoised DAHANCA trials. Euro J Cancer Suppl 2009;7:11.

Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24-35.

Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. HPV-associated p16-expression and response to hypoxic modifi cation of radiotherapy in head and neck cancer: DAHANCA. Radiotherapy and Oncology 2010;94:30-35.

Devaraj K, Gillison ML, Wu TC. Development of HPV Vaccines for HPV-associated Head and neck squamous cell carcinoma. Crit Rev Oral Biol Med 2003;14(5):345-362.

Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645–51.

Lin K, Doolan K, Hung CF, et al. Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc 2010;109(1):4-24.

Trimble C, Frazer IH. Development of therapeutic HPV vaccines. Lancet Oncol 2009;10:975-80.

Gillespie MB, Rubinchik S, Hoel B, Sutkowski N. Human Papillomavirus and oropharyngeal cancer: what you need to know in 2009. Current Treatment Options in Oncology 2009; 10:296-307.

Downloads

Published

2011-06-29

How to Cite

1.
Dankulchai P, Thephamongkhol K, Narawiwat T, Chansilpa Y. Human Papilloma Virus in Oropharyngeal Carcinoma. J Thai Assn of Radiat Oncol [Internet]. 2011 Jun. 29 [cited 2024 Apr. 25];17(1):92-8. Available from: https://he01.tci-thaijo.org/index.php/jtaro/article/view/203492

Issue

Section

Review articles